Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukemia and non-Hodgkin’s lymphoma: Dose-limiting myelosuppression without evidence of DNA hypomethylation

PURPOSE: Targeting aberrant DNA hypermethylation in chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL) with decitabine may reverse epigenetic silencing in B-cell malignancies. METHODS: Twenty patients were enrolled in two phase I trials to determine the minimum effective pharmacolog...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Blum, Kristie A., Liu, Zhongfa, Lucas, David M., Chen, Ping, Xie, Zhiliang, Baiocchi, Robert, Benson, Donald M., Devine, Steven M., Jones, Jeffrey, Andritsos, Leslie, Flynn, Joseph, Plass, Christoph, Marcucci, Guido, Chan, Kenneth K., Grever, Michael R., Byrd, John C.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2010
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2917115/
https://ncbi.nlm.nih.gov/pubmed/20456354
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2010.08213.x
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia